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ABSTRACT
Cys-loop receptors are neurotransmitter-activated ion channels
involved in synaptic and extrasynaptic transmission in the brain
and are also present in non-neuronal cells. As GABAA and
nicotinic receptors (nAChR) belong to this family, we explored
by macroscopic and single-channel recordings whether the in-
hibitory neurotransmitter GABA has the ability to activate
excitatory nAChRs. GABA differentially activates nAChR sub-
types. It activates muscle nAChRs, with maximal peak currents of
about 10% of those elicited by acetylcholine (ACh) and 15-fold
higher EC50 with respect to ACh. At the single-channel level, the
weak agonism is revealed by the requirement of 20-fold higher
concentration of GABA for detectable channel openings, a major
population of brief openings, and absence of clusters of openings
when compared with ACh. Mutations at key residues of the
principal binding-site face of muscle nAChRs (aY190 and aG153)
affect GABA activation similarly as ACh activation, whereas
a mutation at the complementary face («G57) shows a selective
effect for GABA. Studies with subunit-lacking receptors show that
GABA can activate muscle nAChRs through the a/d interface.
Interestingly, single-channel activity elicited by GABA is similar to
that elicited by ACh in gain-of-function nAChR mutants associ-
ated to congenital myasthenic syndromes, which could be
important in the progression of the disorders due to steady
exposure to serum GABA. In contrast, GABA cannot elicit single-
channel or macroscopic currents of a7 or the chimeric a7-
serotonin-type 3 receptor, a feature important for preserving an
adequate excitatory/inhibitory balance in the brain as well as for
avoiding activation of non-neuronal receptors by serum GABA.
Introduction
Nicotinic acetylcholine receptors (nAChR) are members of
the Cys-loop ligand-gated ion channel superfamily that also
includes glycine, serotonin-type 3 (5HT3A), and GABAA
receptors (Bouzat, 2012). a7 nAChRs are among the most
abundant in the central nervous system. They contribute to
cognitive functioning, sensory information processing, atten-
tion, working memory, and reward pathways. Decline or
alterations of signaling involving a7 have been implicated in
neurologic diseases, such as schizophrenia, epilepsy, autism,
and Alzheimer’s disease (Kalamida et al., 2007; Thomsen et al.,
2010;Wallace and Porter, 2011; Hurst et al., 2013; Wallace and
Bertrand, 2013). a7 nAChRs localize both pre- and post-
synaptically, but they dominantly operate in an extrasynaptic
mode (Lendvai and Vizi, 2008). Volume transmission is also
relevant in non-neuronal cells, such as lymphocytes and
macrophages, in which a7 is involved in anti-inflammatory
responses (De Rosa et al., 2009; Andersson and Tracey,
2012). Muscle nAChRs are confined at postsynaptic locations
in muscle fibers and are mainly implicated in myasthenia
gravis and congenital myasthenic syndromes (Engel et al.,
2012).
nAChR subunits are classified as either a, which contain
a disulfide bridge important for acetylcholine (ACh) binding, or
non-a subunits, which lack this motif (Matsuda et al., 2005).
nAChRs assemble from five identical a subunits, such as a7, or
from different a and non-a subunits, such as the muscle
nAChR, which in the adult is composed of two a1, one b, one d,
and one « subunits. The five homologous subunits are arranged
as barrel staves around a central ion-conducting pore (Bartos
et al., 2009). Approximately half of each subunit is extracellu-
lar, with the remainder comprising transmembrane domains
M1–M4 and a large cytoplasmic domain spanning M3 and M4
(Bouzat, 2012). The neurotransmitter binding sites are formed
within the extracellular domain at interfaces between subunits
(Sine et al., 2002). One of the sides, called the principal face, is
formed by three discontinuous loops of the a subunit, whereas
the complementary face is formed by three discontinuous
b-strands of the adjacent subunit, which in the muscle nAChR
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is either the « or the d subunit. Key residues of the principal
face are grouped in regions called loops A, B, and C at the
principal face and loops D, E, and F at the complementary face
(Brejc et al., 2001; Sine and Engel, 2006; Nys et al., 2013).
Residues of the principal face are highly conserved between a7
and a1 subunits, whereas less conservation is found in residues
located at the complementary face (Bartos et al., 2009). The
potential for understanding ligand binding at the atomic
structural level arose with the discovery of acetylcholine-
binding protein (AChBP) (Brejc et al., 2001), a soluble protein
homologous to the ligand binding domains of pentameric
ligand-gated ion channels. Homology models from AChBP
have helped to gain in-depth understanding of how ligands
bind to an ACh binding site.
GABA is the main inhibitor neurotransmitter in the nervous
system and can exert its effects through GABAA receptors
located at inhibitory synapses. However, GABA released at the
synaptic cleft can diffuse and reach receptors outside of the
synapse, on the soma, dendrites, and axon (Kullmann et al.,
2005). Thus, GABA can be involved in both synaptic and
extrasynaptic actions in the brain (Oláh et al., 2009). Moreover,
GABAmight even have a broader spectrum of effects because it
is also present in blood at a concentration of 0.1 mM (Bjork
et al., 2001). Given that GABAA receptors and nAChRs belong
to the same Cys-loop family, we sought to explore whether the
inhibitory neurotransmitter GABA is able to activate excit-
atory nAChRs, thus leading to cross-talk among family
members. To this end, we evaluated the action of GABA at
the neuronal a7 andmuscle nAChR bymacroscopic and single-
channel recordings. Our results demonstrate that GABA has
the ability to activate muscle, but not a7 nAChRs, and provide
insights into the structural and mechanistic differences with
respect to ACh activation.
Materials and Methods
Site-Directed Mutagenesis and Expression of a7 and Adult
Muscle nAChR
BOSC 23 cells, which are modified HEK293 cells (Pear et al., 1993),
were transfectedwithwild-type ormutant subunit cDNAs of adultmuscle
nAChRs: a1, b, «, and d, humana7 ora7-5HT3A using calciumphosphate
precipitation (Bouzat et al., 2002, 2004, 2008). To promote receptor
expression on the cell surface, the human a7 cDNA was cotransfected
with cDNA encoding the chaperone protein RIC-3 (Williams et al., 2005).
A plasmid encoding green fluorescent protein was included in all
transfections to allow the identification of transfected cells under
fluorescence optics. Cells were used for current measurements 48 or 72
hours after transfection. Mutant subunits were constructed using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).
Patch-Clamp Experiments
Single-Channel Recordings. Single-channel currents were re-
corded in the cell-attached configuration (Hamill et al., 1981) at room
temperature. The bath and pipette solutions contained 140 mM KCl,
5.4 mM NaCl, 1.8 mM CaCl2, 1.7 mM MgCl2, and 10 mM HEPES (pH
7.4). For a7-5HT3A, the bath solution contained low calcium (0.2mM) to
avoid open-channel block (Bouzat et al., 2008). Currents were recorded
using an Axopatch 200 B patch-clamp amplifier (Axon Instruments/
Molecular Devices, Sunnyvale, CA), digitized at 5-microsecond inter-
vals, recorded using the Acquire program (Bruxton, Seattle, WA), and
detected by the half-amplitude threshold criterion using the TAC 4.0.10
program (Bruxton). Channels were typically recorded at a membrane
potential of 270 mV. Open and closed time histograms were plotted
using a logarithmic abscissa and a square root ordinate and fitted to the
sum of exponential functions by maximum likelihood using the TACFit
program (Bruxton). Clusters or bursts of openings corresponding to
a single receptor channel were identified as a series of closely spaced
events preceded and followed by closed intervals greater than
a specified duration (tcrit); this duration was taken as the point of
intersection of the predominant closed time component and the
succeeding one in the closed-time histogram (Bouzat et al., 2000).
In some experiments, the tip of the pipette was filled with a solution
containingACh orGABAand the shaftwith the same solution containing
ACh and GABA or GABA and a-bungarotoxin (a-BTX). Channel re-
cordings obtained immediately after seal formation were assigned the
status of control condition. As with time, the shaft solution diffuses to the
tip of the pipette; channels recorded 5–6 minutes after the beginning of
the recording were considered the exposed condition. Only patches in
which the seal was made rapidly were used for this type of analysis.
Whole-Cell Recordings. Currents were recorded in the whole-cell
patch-clamp configuration at a pipette potential of 270 mV at room
temperature. The pipette solution contained 134mMKCl, 5mMEGTA,
1.7 mM MgCl2, and 10 mM HEPES, pH 7.3. The extracellular solution
(ECS) contained 150 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2, and
10 mM HEPES, pH 7.3. Rapid agonist perfusion was performed, as
described before (Corradi et al., 2009). Briefly, the perfusion system
consisted of solution reservoirs suspended on a pole for gravity-driven
flow, switching valves, a solenoid-driven pinch valve, and two tubes
oriented into the culture dish. One tube contained ECSwithout agonist,
and the other contained ECS with agonist. When the pinch valve was
switched, solution flowed from only one side at a time, and switched
from one side to the other. This perfusion system allowed for a rapid
exchange (0.1–1 milliseconds) of the solution bathing the patch.
Macroscopic currents were recorded using an Axopatch 200 B patch-
clamp amplifier (Axon Instruments) and filtered at 5 kHz. Data
analysis was performed using the IgorPro software (WaveMetrics, Lake
Oswego, OR). Current records were aligned at the point at which the
current reached 50% of maximum. Peak currents correspond to the
value obtained by extrapolation of the decay current to this point.
Current decays were fitted by an exponential decay function:
IðtÞ5 I0 expðt=tdÞ1 I‘ (1)
where I0 and I‘ are peak and the steady state current values,
respectively, and td is the decay time constant (Andersen et al., 2011).
EC50 and Hill coefficient values were calculated by nonlinear
regression analysis using the Hill equation:
I=Imax51=½11 ðEC50=LÞnH  (2)
where EC50 is the agonist concentration that elicits the half-maximal
response, nH is the Hill coefficient, and L is the agonist concentration
(Bartos et al., 2006).
Homology Modeling and Molecular Docking
Homologymodels of the extracellular domain of the human neuronal
a7 nAChR and the adult mouse muscle nAChR were created using the
structure of the nicotine-bound Lymnaea stagnalis AChBP (PDB ID
1UW6) as template. The amino acid sequences were aligned using
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/), and modeling
was performed using Modeler 9 v.11 (http://salilab.org/modeler/) (Sali
et al., 1995). We have not included in our analysis loop F of d and «
subunits because it cannot be modeled reliably (Hernando et al., 2012;
Arias et al., 2013). Symmetry constraints were imposed on the Ca
atoms for the same a-type subunit. Ten models were constructed, and
the one with the highest Modeler scores and the smallest percentage of
amino acids in the disallowed region of the Ramachandran plot was
selected for docking studies. ACh or GABA molecules were docked
separately into the agonist binding sites located at a–d, a–«, or each of
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the five a7–a7 interfaces using AutoDock version 4.3 (Morris et al.,
2009). The ligand binding site was defined as being within 20 Å of
W149. One hundred genetic algorithm runs were performed for each
condition. Clustering of the results was done with AutoDock based on
a root-mean-square deviation cutoff of 2.0 Å. Docking results were
corroborated in four different procedures. Best docking poses for each
drug and interface were plotted with Discovery Studio Visualizer 3.5
(Accelrys Software, San Diego, CA).
Statistics. Experimental data are shown asmean6S.D. Statistical
comparisons were done using the Student’s t test. P , 0.05 was
considered significant.
Results
GABA Activates Muscle nAChRs. To evaluate whether
the neurotransmitter GABA is able to activate muscle nAChR,
we first recorded macroscopic currents in the whole-cell
configuration from cells transfectedwith a1, b, d, and « subunits.
At concentrations higher than 25 mM, GABA elicits macroscopic
responses of adultmuscle nAChR.Maximal responses elicited by
500 mMGABA are 10.56 3.5% of those elicited by 500 mMACh
(Fig. 1A). Expressing the relative peak current as a function of
agonist concentration results in values of EC50 of 18 6 1.1 mM
(nH5 2.76 0.7, n5 3) and 2686 80 mM (nH5 0.76 0.2, n5 3)
for ACh andGABA, respectively (Fig. 1A). These results indicate
that GABA has the ability to activate muscle nAChRs, although
it behaves as a very low-efficacy agonist.
To reveal the basis underlying partial activation of muscle
nAChR by GABA, we performed single-channel recordings
(Fig. 1B). Single-channel openings are readily detected at
GABA concentrations as low as 1 mM GABA. Activity appears
mainly as isolated openings flanked by long closings (Fig. 1B).
For GABA concentrations lower than 1 mM, the frequency of
openings was markedly low andmany patches appeared silent.
To unequivocally confirm that the detected channel activity
arises from GABA-activated nAChRs and not from endogenous
GABA receptors, we recorded single channels from cells
transfected only with green fluorescent protein (GFP) cDNA,
and, in parallel, from cells of the same batch transfected with
GFP and nAChR-subunit cDNAs. Whereas no channels are
detected in cells expressing GFP alone, nAChR-expressing cells
show clear single-channel activity in the presence of 1 mM
GABA. Also, the mean amplitude of opening events detected
from cells expressing muscle nAChR is similar for recordings
performed in the presence of 1 mMACh (5.676 0.06 pA, n5 3,
270 mV) or 1 mM GABA (5.61 6 0.17 pA, n 5 3, 270 mV).
At all tested GABA concentrations (1 mM–10mM), open time
histograms are fitted by two components (Supplemental Table 1).
The duration of the slowest open component is similar to that of
ACh-activated channels (∼1 millisecond; Supplemental Table 1)
(Bouzat et al., 2000, 2002). In the presence of GABA, the long
openings correspond to only 30% of total openings and themain
population of events is composed of brief openings (mean open
duration ∼100 microseconds). In contrast, long openings are
predominant in the presence of ACh (.75% at 1 mM ACh)
(Table 1). At ACh concentrations higher than 10 mM, muscle
nAChR opens in clusters of well-defined activation episodes
(Fig. 1B) (Bouzat et al., 2002). Each activation episode, named
cluster, begins with the transition of a single receptor from
the desensitized to the activatable state and terminates by
returning to the desensitized state. Closed time histograms
for ACh show a main intracluster component that is sensitive
to ACh concentration (Bouzat et al., 2000) (Fig. 1B). GABA can-
not elicit activation in clusters at any concentration (1 mM–
10 mM) (Fig. 1B). Also, closed time histograms do not show a
component sensitive to GABA concentration as observed for
ACh (Fig. 1B). These results explain why GABA acts as a low-
efficacy agonist of muscle nAChR.
We also performed single-channel recordings with a pipette
in which the tip was filled with the solution containing 1 mM
GABA and the shaft was filled with the same solution
containing 1 mM GABA and 1 mM a-BTX. Single-channel
openings were readily detected in the first seconds after seal
formation, and then channel activity profoundly decreased as
a function of time (Fig. 1C). As a control, we verified that
specific labeling of Alexa Fluor 594 a-BTX was not detected in
our untransfected cells, in good agreement with previous
report in HEK cells (McCann et al., 2006).
This result demonstrates that the detected channel activity
arises from nAChR and that GABA-activated channels are
blocked by a-BTX.
Activation by GABA of Mutant Muscle nAChRs. We
next evaluated how mutations at the principal and comple-
mentary faces of the binding site that affect ACh activation
also affect activation by GABA.
The amino acid aY190 located at loop C of the principal face
of the binding site has been shown to be essential for muscle
(Sine et al., 1994) and a7 (Rayes et al., 2009; Andersen et al.,
2013) nAChR activation. The mutation aY190F decreases ACh
affinity and the efficacy of activation (Chen et al., 1995; Purohit
and Auerbach, 2011; Williams et al., 2011). At the single-
channel level, the changes are evidenced by the absence of
clusters at high ACh concentrations and briefer opening events
(Fig. 2; Table 1). GABA (1mM–10mM) does not elicit detectable
single-channel activity (n 5 14) in good agreement with the
reduced activation shown for ACh (Table 1).
aG153, located in loop B of the principal side, is a key residue
for ACh activation of mammalian muscle and neuronal a7
nAChRs (Grutter et al., 2003; Jadey et al., 2013). Single-channel
kinetic analysis ofaG153SnAChR revealed amarkedly decreased
rate of ACh dissociation, which causes themutant nAChR to open
repeatedly forming bursts (Sine et al., 1995; Rayes et al., 2004)
(Fig. 2). In the presence of GABA, kinetic changes are qualita-
tively similar to those observed in the presence of ACh. Channel
openings appear in clear bursts (0.1–500 mMGABA) (Fig. 2).
The mean durations of the slowest open component (∼1.7
milliseconds; Table 1) and of bursts (4.53 6 1.69 milliseconds,
relative area 5 0.26 6 0.16, n 5 4) are briefer than those de-
termined in the presence of ACh (∼3.7milliseconds [Table 1] and
10.18 6 0.35 milliseconds [relative area 5 0.61 6 0.05, n 5 3]
for mean open and burst durations, respectively, P , 0.01).
Position 57 of loopD of the complementary face of the binding
site has been shown to be a determinant of drug selectivity
(Bartos et al., 2006, 2009). Recordings from nAChR containing
the mutant «G57Q subunit show increased open durations for
GABA-activated channels, but not for ACh-activated channels
with respect to wild-type nAChRs (P , 0.01, n 5 3) (Table 1).
For receptors carrying the dD57Q mutation, no detectable
differences in the mean open duration for both GABA and ACh
are observed (Table 1) (P . 0.05, n 5 5).
Overall, binding site mutations at the principal face affect
similarly GABA and ACh activation, whereas position 57 of
the « subunit located at the complementary face changes
GABA, but not ACh activation.
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To gain more insights into GABA activation, the importance
of the a/d binding-site interface was evaluated by studying
activation of nAChR lacking the « subunit. In the absence of
this subunit, nAChRs contain two a/d binding-site interfaces
instead of one a/d and one a/« interface as in wild-type nAChR.
These receptors express well in cells and are activated by ACh
(Bouzat et al., 1994). ACh-elicited openings are more prolonged
than those of wild-type nAChR (Fig. 3A). The mean duration
of the slowest open component for ACh-activated channels is
5.27 6 1.37 milliseconds (relative area 5 0.77 6 0.13, n 5 3)
instead of ∼1 millisecond for wild-type nAChR. GABA (10 mM)
also elicits single-channel currents from a2bd2 receptors (Fig.
3A), indicating that this agonist is capable of activating nAChR
through the a/d interface. In agreement with ACh-elicited
activity, the duration of the slowest open component (1.606 0.40
milliseconds, relative area 5 0.10 6 0.05, n 5 4) is longer than
that of wild-type nAChR when GABA is the agonist (P , 0.05).
Although spontaneous activity of a2bd2 receptors has been
reported (Zhou et al., 1999), we were not able to record clearly
detectable openings in this study in the absence of agonist. This
Fig. 1. Activation of adult muscle nAChR by GABA. (A)
Left, whole-cell currents recorded in response to rapid
perfusion of 500 mM ACh or 500 mM GABA. The solid
bar indicates the duration of exposure to the drug. Each
curve is the average of two to four drug applications.
Right, dose-response curves for ACh (open symbols) and
GABA (solid symbols) of muscle nAChR. Each point is
the average of three to five determinations, with the
error bars representing the S.D. of the mean value.
Curves are fits to the Hill equation. Membrane
potential: 270 mV. (B) Single channels activated by
1 and 1000 mM GABA and 1 and 60 mM ACh recorded
from cells expressing adult muscle nAChR. Left, traces
of currents are shown at a bandwidth of 10 kHz with
channel openings as upward deflections. Right, open
and closed time histograms corresponding to each
condition. Membrane potential: 270 mV. (C) Single-
channel recordings activated by 1000 mM GABA and
1 mM a-BTX were recorded from cells expressing adult
muscle nAChR. The tip of the pipette was filled with
a solution containing only GABA, and the shaft with the
solution containing GABA and a-BTX. After the first
minute of recording, a marked decrease of channel
activity was observed. Traces are shown at a bandwidth
of 7 kHz with channel openings as upward deflections.
The inset shows an opening event at higher time
resolution. Membrane potential: 270 mV.
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difference may be due to differences in receptor expression
because the open probability of ligand-free activated receptors is
very low. Thus, we can ensure that the detected openings arise
from GABA-activated nAChR.
The mutation «T264P at the M2 domain of the « subunit,
which has been first described in a patient suffering from
a slow-channel congenital myasthenic syndrome, leads to gain
of function (Ohno et al., 1995; Engel et al., 2012). In the absence
of ACh, spontaneous activity of the mutant «T264P nAChR is
evidenced by the presence of brief openings (Fig. 3B), being the
mean duration of the longest duration open component of 1.56
0.3 milliseconds (relative area 5 0.05 6 0.01, n 5 3). In the
presence of ACh (1 mM) or GABA (0.1–100 mM), significantly
prolonged openings are observed (Fig. 3B). Open time histo-
grams are fitted by three components, and the slowest one,
which is not detected in the absence of agonist, shows a mean
duration of 20.62 6 7.84 milliseconds for 1 mM ACh (relative
area 5 0.56 6 0.08, n 5 3) and 28.45 6 3.45 milliseconds for
0.1 mMGABA (relative area5 0.816 0.05, n5 3). Thus, GABA
behaves very similar to ACh in this M2 mutant receptor.
GABA Cannot Activate a7 nAChR. We evaluated
whether GABA is able to activate human a7 and the high
conductance form of the chimeric a7-5HT3A receptor, which is
a good model for studies of a7 because it shows high surface
TABLE 1
Open durations of wild-type and mutant muscle nAChR activated by ACh and GABA
Single-channel recordings were performed from cells expressing muscle wild-type receptors or receptors containing the
indicated mutant subunit. Open duration components were obtained from the open time histograms. Data are shown as
mean 6 S.D. for at least three recordings for each condition. For aY190F, single-channel activity in the presence of GABA
was not detected in 14 different patches from GFP-transfected cells (green cells).
Receptor Agonist mM Open 1 (ms) (Relative Area) Open 2 (ms) (Relative Area)
Wild-type ACh 1 0.99 6 0.10 (0.70 6 0.12) 0.24 6 0.07 (0.30 6 0.13)
GABA 1 0.76 6 0.12 (0.31 6 0.04) 0.10 6 0.03 (0.69 6 0.04)
aY190F ACh 60 0.58 6 0.17 (0.11 6 0.06) 0.19 6 0.05 (0.89 6 0.06)
GABA 1–10,000 nd nd
aG153S ACh 1 3.76 6 0.29 (0.67 6 0.07) 0.36 6 0.04 (0.32 6 0.07)
GABA 1 1.68 6 0.40 (0.39 6 0.157) 0.18 6 0.02 (0.60 6 0.157)
«G57Q ACh 1 0.88 6 0.0 (0.18 6 0.12) 0.32 6 0.03 (0.82 6 0.12)
GABA 1000 1.91 6 0.33 (0.11 6 0.01) 0.24 6 0.03 (0.89 6 0.01)
dD57Q ACh 1 1.18 6 0.25 (0.67 6 0.08) 0.32 6 0.06 (0.33 6 0.08)
GABA 1000 1.55 6 0.59 (0.06 6 0.02) 0.16 6 0.02 (0.93 6 0.01)
nd, not detected.
Fig. 2. Activation of mutant muscle nAChRs by GABA.
Left, channels were recorded from BOSC 23 cells
expressing nAChR containing the mutant aY190F,
aG153S, «G57Q, or dD57Q subunits. Currents are
shown at a bandwidth of 7 kHz with channel openings
as upward deflections. Right, open and closed time
histograms of nAChRs carrying the specified mutant
subunit. The data are representative of four to six
recordings for each condition. Membrane potential:
270 mV.
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expression and channel activity is easily detected (Rayes et al.,
2005; Andersen et al., 2011). In cells transfected with a7 (Fig.
4A) or a7-5HT3A (Fig. 4B), macroscopic currents are elicited by
300 mM ACh (Bouzat et al., 2008). In contrast, application of 1–
10 mMGABA to cells showing ACh responses does not generate
detectable macroscopic currents (Fig. 4). No single-channel
activity from cells expressing a7 (n5 18) or a7-5HT3A receptors
(n 5 20) is detected in the presence of 100–1000 mM GABA. In
contrast, typical single-channel openings withmean durations of
∼0.28 milliseconds for a7 (100 mM ACh) and ∼9.5 milliseconds
for a7-5HT3A (500 mM ACh) (Rayes et al., 2005; Bouzat et al.,
2008) are detected (Fig. 4, A and B). In the a7-5HT3A receptor,
we testedwhether amutation at position 153 of the extracellular
domain (a7G153E), which has been shown to increase efficacy in
muscle and a7 nAChRs (Bartos et al., 2006; Jadey et al., 2013),
allows detectable single-channel activity elicited by GABA. In
contrast to the results observed in muscle nAChR, channel
activity was not detected in the presence of GABA in a7-5HT3A
carrying theG153Emutation (500 and 1000mM, n5 13) (Fig. 4C).
We also explored whether the presence of GABA affects
a7 activity. To this end, we recorded a7-5HT3A channels in
the presence of 300 mM ACh in the tip of the pipette and
300 mM ACh plus 10 mM GABA in the shaft. Under these
conditions, competition of GABA should be evidenced as
a marked reduction of the frequency of channel openings
with time of recording due to the diffusion of GABA to the
pipette tip. The time-dependent decrease in channel
activity (67%), which was measured by the decrease in
the number of openings/min between minutes 1 and 5 of
the recording, was not markedly different from that ob-
served for control conditions—only ACh present (61%)—thus
evidencing that GABA does not antagonize ACh action at
a7 receptors.
Docking of GABA into nAChRs. To gain insights into
how GABA may interact with nAChRs, we performed in silico
studies. For the adult muscle nAChR, docking of ACh in both
a–« and a–d interfaces resulted in only one energetically
favorable model, with best binding energy (BBE) of 25.0 kcal/
mol. We observed the well known cation-p interaction between
the positively charged group of ACh and the aromatic ring of
aW149 (Dougherty, 2007). ACh also showed the possibility to
form a hydrogen bond between its carbonyl group and the polar
backbone hydrogen of dL121 or «L119, a hydrogen bond with d2
or «2Y104, and to interact with W55 at the complementary face
(Fig. 5A for a/«).
For GABA, two plausible models were detected for the a–«
interface, named model 1 (Fig. 5B) and model 2 (Fig. 5C), with
BBE of23.5 and23.0 kcal/mol, respectively. The probability to
adopt one orientation or the other appears to be similar. For the
a–d interface, all docking runs were clustered into only one
group with a similar orientation and BBE as that of model 1.
Model 1 is able to reproduce most of the features of ACh
interaction (Fig. 5B). The carboxyl group of GABA shows the
potential to form a hydrogen bond with Y104 and dL121 or
«L119 of the complementary face, and the ammonium group
shows the potential to form hydrogen bonds with the oxygen of
the backbone of aW149 (Hibbs et al., 2009; Xiu et al., 2009). The
cation-p interaction with the indole group of W149 is also
present. In model 2, GABA adopts a different orientation (Fig.
5C). Although the cation-p interaction and the hydrogen bond
with W149 are present, its carboxyl group is oriented toward
the lower part of the cleft containing aromatic residues, thus
avoiding other possible interactions with residues of loop E
from the complementary face (Supplemental Fig. 1). In model 2
orientation, GABA does not occupy the same space as ACh
within the binding pocket, and it may have the potential to
interact with loop A and to form a hydrogen bond with Y93
(Hansen et al., 2005; Rucktooa et al., 2009).
For each a7–a7 interface, docking of ACh resulted in only
one energetically favorable model with BBE of 25.0 kcal/
mol (Fig. 5D). All interactions are similar to those observed
for muscle interfaces, with the exception of the hydrogen
bond with Y104, which is phenylalanine in a7. In con-
trast, GABA shows two plausible models, with similar
Fig. 3. (A) Activation of triplet a2bd2 nAChRs.
Single channels activated by 1 mM ACh and
10 mM GABA were recorded from cells expressing
adult muscle nAChR lacking the « subunit. Left,
traces of currents are shown at a bandwidth of
7 kHz with channel openings as upward deflec-
tions. Right, open and closed time histograms
corresponding to each condition. The data are
representative of four recordings for each condi-
tion. Membrane potential: 270 mV. (B) Activa-
tion of «T264P mutant nAChR. Single channels
were recorded from cells expressing adult muscle
nAChR carrying the «T264P mutation on the M2
domain in the absence of agonist, and in the
presence 1 mMACh or 0.1 mMGABA. Left, traces
of currents are shown at a bandwidth of 7 kHz
with channel openings as upward deflections.
Right, open and closed time histograms corre-
sponding to each condition. The data are repre-
sentative of five recordings for each condition.
Membrane potential: 270 mV.
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orientations to those in a–« interface. However, the prob-
ability to adopt model 2 conformation is twofold higher
than that of model 1. In model 1 orientation, it shows the
potential to form the cation-p interaction and the hydrogen
bond with W149 (Fig. 5E). GABA may also form hydrogen
bonds with L119 and with N107, which is not observed
in our model of muscle nAChR interfaces. In model 2
orientation, the majority of key interactions are similar to
those observed in the muscle nAChR (Fig. 5F; Supplemen-
tal Fig. 1).
Discussion
In this study, we demonstrate that GABA behaves as
a partial agonist of themuscle nAChR, but cannot activate the
neuronal a7 nAChR.
Fig. 4. Action of GABA on a7 nAChR. (A and B) Left,
macroscopic current recordings activated by 1000 mM
GABA (gray line) or 300 mM ACh (black line) from cells
expressing a7 (A) or a7-5HT3A receptors (B). The solid
line above the traces represents the pulse of agonist.
Each trace is representative of four recordings for each
condition. Membrane potential: 270 mV. Right, single-
channel traces from cells expressing a7 (A) or a7-5HT3A
receptors (B). Traces of currents are shown at a band-
width of 7 kHz with channel openings as upward
deflections. The data are representative of 10 or
20 recordings for each condition. Membrane potential:
270 mV. (C) Single-channel traces corresponding to
a7-5HT3A receptors carrying the a7G153E mutation
activated by 500 mM ACh or 1000 mM GABA (no
channels detected, n = 13). Openings are shown as
upward deflections at a bandwidth of 9 kHz. Membrane
potential: 270 mV.
Fig. 5. Molecular docking of ACh or GABA to muscle a/«
(top) or a7/a7 (bottom) interfaces. Homology models of a/«
(A–C) (Supplemental Material; a–« interface) and a7/a7
interfaces (D–F) (Supplemental Material; a7–a7 inter-
face) were generated using the structure of the AChBP
(PDB ID 1UW6), as described in the text. The subunits
are colored cyan (a), red («), and pink (a7), and the
corresponding residue atoms are colored as follows: gray
for C, violet for N, red for O, and light gray for H. ACh and
GABA carbons are colored green. The labeled residues
are conserved among interfaces, except F103 in the a7
subunit of the complementary face, which corresponds to
Y104 in the « subunit. The interactions of ligands with
important residues of the binding site are also shown.
Hydrogen bonds are shown with black dashed lines and
cation-p interactions with solid lines.
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Macroscopic current recordings show that maximal peak
currents of muscle nAChRs elicited by GABA are only 10% of
those elicited by ACh, and dose-response curves show that the
EC50 is 15-fold higher for GABA than ACh, indicating that
GABA is a low-efficacy agonist of the muscle nAChR. At the
single-channel level, the mechanistic basis of this weak
agonistic efficacy is revealed by the following: 1) the re-
quirement of ∼20-fold higher concentration of GABA than
ACh (1 mM instead of 50 nM for ACh) (Spitzmaul et al., 2004)
for detectable reliable channel activity; 2) the presence of
a major population of brief openings; and 3) the absence of
clusters at all GABA concentrations, in contrast to what is
observed with ACh or other agonists (Bouzat et al., 2000).
We explored whether GABA requires similar residues to
those shown for efficient ACh activation in themuscle nAChR.
We demonstrated that key residues of the principal face, Y190
located in loop C and G153 located in loop B, are also required
for GABA activation of muscle nAChR. The effects of aY190F
and aG153S mutations on muscle nAChR activation have
been well characterized (Sine et al., 1995; Salamone et al.,
1999; Grutter et al., 2003; Rayes et al., 2004; Mukhtasimova
et al., 2009; Purohit and Auerbach, 2011, 2013; Jadey et al.,
2013). In parallel with the changes observed for ACh, GABA
responses are increased in aG153S mutant and are negligible
in aY190F mutant.
Position 153 at loop B of the binding site has been shown to
be associated with a slow-channel syndrome (Sine et al.,
1995), to be involved in the high efficacy of activation of
nematode nAChRs by anthelmintic drugs (Rayes et al., 2004),
to affect gating in neuronal nAChR (Grutter et al., 2003), and
to affect agonist efficacy of muscle nAChR (Purohit and
Auerbach, 2011). GABA is capable of eliciting bursts of
openings, which are significantly prolonged in the aG153S
when compared with the wild-type nAChR. Nevertheless,
open and burst durations are briefer than those determined in
the presence of ACh. This result indicates that these
positions, Y190 and G153, are not determinants of GABA
partial agonism, but they are important for GABA as well as
for ACh activation.
Our study reveals that the residue at position 57 located in
loop D of the complementary face of the a/« binding site is
a key determinant of the action of GABA at muscle nAChR.
The mutation «G57Q selectively increases the efficacy of
GABA activation, as evidenced by significantly increased
open channel durations and by the presence of bursts. As
described before (Bartos et al., 2009), ACh activation is not
modified in the mutant «G57Qwith respect to the control. The
equivalent mutation in the d subunit does not affect either
GABA or ACh activation. These results suggest that GABA
binds to the a/« interface, and that «G57 is involved in its
activation. An alternative explanation could be that GABA
does not bind to the a–« interface except in the presence of the
«G57Qmutation. Under this hypothesis, the major proportion
of brief openings detected in wild-type nAChRs would
correspond to openings of single-liganded receptors (a/d
interface). The mutation would lead to more prolonged
openings—corresponding to biliganded receptors—by allow-
ing binding of GABA to the a/« interface. For this to occur,
GABA must be able to bind to the a/d interface. To test this
possibility, we studied receptors lacking the « subunit
because, unfortunately, it is not possible to detect channel
openings from d-lacking receptors (Bouzat et al., 1994; Zhou
et al., 1999). We found that GABA is capable of mediating
activation through the a/d interface. In the presence of GABA,
single-channel currents from a2bd2 occur in bursts of
prolonged openings, which are significantly different from
those detected in the absence of agonist, thus indicating that
GABA can activate the receptor through the a/d interface. The
mutation «G57Q has been shown to increase significantly
the efficacy of morantel activation (Bartos et al., 2009). Thus,
the present results reinforce the role of position 57 as a de-
terminant of selectivity for a broader spectrum of drugs
(Shimomura et al., 2002; Bartos et al., 2006).
Docking studies showed only one possible way of interac-
tion of ACh and of GABA at the a/d interface, but two of
GABA at a/« and a7/a7 interfaces. Models 1 and 2 differ in
the orientation of the GABA molecule, which can form the
H-bonds and cation-p interactions with key residues of the
binding site (Y93, W149 of the principal face and Y104, N107
or L119/L121 of the complementary face), similar to those
observed for ACh and other agonists. In light of these
observations, the partial agonism of GABA at muscle nAChRs
may be explained by its ability of adopting multiple
orientations at the binding site, as reported previously for
other partial agonists (Hibbs et al., 2009). Considering our
experimental evidence that GABA can activate nAChR
through the a/d subunit interface, we can suggest that model
1 corresponds to the most probable orientation associated
with activation. The apparent controversy between our
experimental results, which reveal lack of functional in-
teraction of GABA with a7, and our docking results, which
show GABA orientations at a7/a7 similar to those at a/«, may
have different explanations. A possible explanation is related
to the prevalence of model 2 orientation in a7, in which GABA
does not occupy the same space as ACh within the binding
pocket, and it may therefore neither be able to elicit receptor
activation nor to compete with ACh. It could be also possible
that, although the overall orientations of GABA appear
similar in a/« and a7/a7 interfaces, differences in specific
potential interactions may be involved in the differential
selectivity. Also, loop F, which could not be included in our
homology models, may be involved in the differential actions
of GABA because it has been shown to be a determinant for
drug selectivity and partial agonism (Stokes et al., 2004;
Hibbs et al., 2009). Alternatively, other residues located
outside the binding site, but involved in coupling agonist
binding to channel opening, may influence the capability of
GABA to activate muscle, but not a7 nAChRs. Although
conclusions from our docking results should be considered
with caution, they open doors for further research.
Plasma GABA concentration in healthy individuals is about
0.1 mM (Bjork et al., 2001). It has been proposed that
peripheral lymphocytes, which have a complete GABAergic
system (Dionisio et al., 2011), could be a source of plasmatic
GABA. The lack of a7 activation by GABA is therefore
important because this receptor is present in blood cells
(Wessler and Kirkpatrick, 2008; De Rosa et al., 2009), and it is
therefore continuously exposed to serum GABA. Even at
higher GABA concentrations, a7 cannot be activated by
GABA, which is also important to avoid cross-talk at the
synaptic level by spillover of GABA, which may diffuse locally
(Fabian-Fine et al., 2001; Zago et al., 2006). It would be
interesting to explore whether other neuronal nAChRs, such
as a4b2, can be activated by GABA.
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Serum GABA concentration is not high enough to activate
muscle nAChRs. However, we found that mutant muscle
nAChRs associated with slow-channel congenital myasthenic
syndromes (aG153S and «T264P mutants) are activated by
0.1 mM GABA, a concentration reached in plasma. For both
gain-of-function receptors, single-channel activity in the
presence of GABA is significantly different from that observed
in the absence of neurotransmitter. Moreover, the mean
duration of both bursts and openings is similar for ACh- and
GABA-activated «T264P nAChRs. Thus, slow-channel con-
genital myasthenic syndrome nAChRs at the neuromuscular
junction are likely to be activated by steady exposure to serum
GABA. This continuous channel activity may contribute to the
pathophysiology of the disease. Interestingly, a similar effect
has been proposed for serum choline at nAChR from slow-
channel congenital syndromes (Zhou et al., 1999).
In conclusion, GABA cannot activate neuronal a7 receptors,
a feature extremely important for preserving an adequate
excitatory/inhibitory balance. In contrast, muscle nAChRs are
partially activated by GABA, and mutations at the principal
face of the binding site affect GABA activation in the same
manner as ACh activation. This activity elicited by GABA
could be important in the progression of congenital myas-
thenic syndromes associated with gain-of-function mutations.
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